Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Associated Therapies: -

Clinical Trials

Study of Axitinib and Temsirolimus in Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Temsirolimus
Drug: Axitinib

First Posted Date: 2012-02-08

Last Posted Date: 2015-04-13

Lead Sponsor: Emory University

Target Recruit Count: 13

Registration Number: NCT01529138

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Phase II Study of Alternating Sunitinib and Temsirolimus

Phase 2

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Sunitinib
Drug: Temsirolimus

First Posted Date: 2012-01-25

Last Posted Date: 2023-09-21

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 37

Registration Number: NCT01517243

Locations: 🇺🇸
University of Vermont, Vermont Cancer Center, Burlington, Vermont, United States
🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

Phase 2

Completed

Conditions: Ovarian Neoplasms
Endometrial Neoplasms
Genital Diseases, Female
Ovarian Diseases

Interventions: Drug: Temsirolimus

First Posted Date: 2011-10-27

Last Posted Date: 2016-02-29

Lead Sponsor: AGO Study Group

Target Recruit Count: 47

Registration Number: NCT01460979

Locations: 🇩🇪
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein, Germany
🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
🇩🇪
Universitätsklinikum Gießen-Marburg, Standort Marburg, Marburg, Hessen, Germany

and more 15 locations

Temsirolimus In Phase 0

Early Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Temsirolimus

First Posted Date: 2011-08-16

Last Posted Date: 2014-06-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT01417065

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Childhood T Acute Lymphoblastic Leukemia
Childhood B Acute Lymphoblastic Leukemia
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Lymphoblastic Lymphoma

Interventions: Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Mitoxantrone Hydrochloride
Drug: Pegaspargase
Other: Pharmacological Study
Drug: Temsirolimus
Drug: Vincristine Sulfate

First Posted Date: 2011-07-27

Last Posted Date: 2015-07-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT01403415

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
C S Mott Children's Hospital, Ann Arbor, Michigan, United States

and more 28 locations

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Phase 2

Active, not recruiting

Conditions: Advanced Rare Tumours

Interventions: Drug: Sunitinib
Drug: Temsirolimus

First Posted Date: 2011-07-18

Last Posted Date: 2024-02-26

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 137

Registration Number: NCT01396408

Locations: 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 14 locations

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: Temsirolimus
Drug: Pazopanib
Behavioral: Quality of Life Assessment
Drug: Benadryl

First Posted Date: 2011-07-12

Last Posted Date: 2021-09-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT01392183

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Phase 1

Completed

Conditions: Refractory Marginal Zone Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Non-Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma
Recurrent Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Follicular Lymphoma
Refractory Mantle Cell Lymphoma
Recurrent Waldenstrom Macroglobulinemia

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Biological: Rituximab
Drug: Temsirolimus

First Posted Date: 2011-06-27

Last Posted Date: 2021-10-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT01381692

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States

and more 8 locations

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: Pimasertib
Drug: Temsirolimus

First Posted Date: 2011-06-22

Last Posted Date: 2018-07-30

Lead Sponsor: EMD Serono

Target Recruit Count: 33

Registration Number: NCT01378377

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
For Recruiting Locations in the US contact US Medical Information in, Rockland, Massachusetts, United States

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Adult Solid Neoplasm

Interventions: Drug: Ixabepilone
Other: Pharmacological Study
Drug: Temsirolimus

First Posted Date: 2011-06-17

Last Posted Date: 2024-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT01375829

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy